GW Pharmaceuticals Ltd
13
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
46.2%
6 terminated/withdrawn out of 13 trials
50.0%
-36.5% vs industry average
31%
4 trials in Phase 3/4
100%
6 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
Role: collaborator
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Role: collaborator
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Role: collaborator
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Role: collaborator
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
Role: collaborator
A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects
Role: lead
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
Role: lead
A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.
Role: lead
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
Role: lead
A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
Role: lead
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
Role: lead
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.
Role: lead
Neuroprotection by Cannabinoids in Huntington's Disease
Role: collaborator
All 13 trials loaded